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RESUmEn 
Objetivo: Identificar las causas de la subno-
tificación de  la Reacción Adversa a Medica-
mento (RAM) por profesionales de la salud. 
Método: Revisión sistemática realizada en 
las bases de datos LILACS, PAHO, SciELO, 
EMBASE y PubMed, cuyo período de revi-
sión fue de 1992 a 2012. Se utilizaron des-
criptores para buscar los artículos. Las cau-
sas de subnotificación identificadas fueron 
analizadas de acuerdo con la clasificación 
de Inman. Resultados: Se identificaron 149 
artículos, de los cuales 29 fueron seleccio-
nados. La mayoría de los estudios fueron 
realizados en hospitales (24/29) para mé-
dicos (22/29) y farmacéuticos (10/29). Las 
principales causas relacionadas a la sub-
notificación observadas fueron: la igno-
rancia (24/29), la inseguridad (24/29) y la 
indiferencia (23/29). Conclusión: Los datos 
evidencian el octavo pecado de la subno-
tificación, que es la falta de formación en 
farmacovigilancia. Por lo tanto, la educaci-
ón continua puede aumentar la adhesión 
de los profesionales al servicio y mejorar el 
conocimiento y la comunicación de riesgos 
del uso de medicamentos.
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RESUmo 
Objetivo: Identificar as causas de subnoti-
ficação de Reação Adversa a Medicamento 
(RAM) por profissionais da saúde. Método: 
Revisão sistemática realizada nas bases de 
dados LILACS, PAHO, SciELO, EMBASE e 
PubMed, cujo período de abrangência foi 
de 1992 a 2012. Foram utilizados descri-
tores para buscar os artigos. As causas de 
subnotificação de RAM identificadas foram 
analisadas de acordo com a classificação 
de Inman. Resultados:  Identificaram-se 
149 artigos, dos quais 29 foram conside-
rados elegíveis. A maioria dos estudos foi 
conduzida em hospitais (24/29), para mé-
dicos (22/29) e farmacêuticos (10/29). As 
principais causas relacionadas à subno-
tificação observadas foram: a ignorância 
(24/29), a insegurança (24/29) e a indife-
rença (23/29). Conclusão: Os dados evi-
denciam o oitavo pecado da subnotifica-
ção, que é a falta de formação em farmaco-
vigilância. Assim, a educação permanente 
pode aumentar a adesão dos profissionais 
ao serviço e melhorar o conhecimento e a 
comunicação dos riscos associados ao uso 
de medicamentos.
 
dESCRitoRES
Sistemas de Notificação de Reações Adver-
sas a Medicamentos
Pessoal de saúde
Farmacovigilância
Vigilância de produtos comercializados
Educação continuada
Revisão
AbStRACt 
Objective: Identifying the main causes for 
underreporting of Adverse Drug Reaction 
(ADR) by health professionals. Method: A 
systematic review carried out in the follo-
wing databases: LILACS, PAHO, SciELO, 
EMBASE and PubMed in the period be-
tween 1992 and 2012. Descriptors were 
used in the search for articles, and the 
identified causes of underreporting were 
analyzed according to the classification of 
Inman. Results: In total, were identified 
149 articles, among which 29 were se-
lected. Most studies were carried out in 
hospitals (24/29) for physicians (22/29), 
and pharmacists (10/29). The main causes 
related to underreporting were ignorance 
(24/29), insecurity (24/29) and indifferen-
ce (23/29). Conclusion: The data show the 
eighth sin in underreporting, which is the 
lack of training in pharmacovigilance. The-
refore, continuing education can increase 
adherence of professionals to the service 
and improve knowledge and communica-
tion of risks due to drug use.
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intRodUCtion
Spontaneous reporting of adverse drug events 
(ADEs) comprise the primary method for detecting 
signs in pharmacovigilance, because they are effective 
for identifying serious unexpected adverse drug reac-
tions (ADRs), medication errors, therapeutic ineffec-
tiveness and inconsistencies in drug quality, besides its 
low cost(1).
It is estimated that between 5% and 10% of ADR are 
reported(2-4). Thus, the main limitation of the passive 
method of analysis of drug safety is cases underreport-
ing(5), which decreases the sensitivity for detecting ADE, 
making it difficult to estimate the frequency of occur-
rence, as well as assessing the severity and impact on the 
health of drug users(6).
For improving the voluntary adhesion of health pro-
fessionals in the assessment of drug safety, and to in-
crease rates of ADR reporting, some actions are neces-
sary. It is important to identify the causes that lead to 
underreporting of problems related to the use of drugs 
by health professionals, in order to establish strategies 
that will be developed for encouraging the communica-
tion of risks associated with drug use and provide safe-
ty guarantees for patients. In this context, the objec-
tives of this study were: 1) identifying the manuscripts 
that analyzed the causes associated with poor adher-
ence of health professionals to the passive method of 
pharmacovigilance service and, 2) proposing strategies 
designed to improve the rates of spontaneous report-
ing of ADR.
mEtHod
The systematic review was carried out in the databas-
es of LILACS, PAHO, SciELO, EMBASE and PubMed, look-
ing for items to answer the guiding question: What causes 
that health professionals do not realize the pharmacovigi-
lance notification?
The search strategy used was based on the PRISMA 
Statment(7), using the following health descriptors: Sur-
veillance of Marketed Products AND Adverse Drug Reac-
tion Reporting Systems AND Attitude of Health Staff. The 
following keywords were also used to complement the 
search: ADR, underreporting of ADRs, notification rate of 
ADRs, adverse drug reactions (ADRs), under-reporting of 
ADRs and attitudes and reporting behavior. 
The technique of content analysis was used for se-
lecting the articles(8). The initial reading of all articles 
identified by the elaborate search technique was done 
(N=149), covering the period between 1992 and 2012. 
The goal was to eliminate the articles that were not in 
English, Portuguese or Spanish; unavailable manuscripts; 
reviews; educational interventions; editorials; letters to 
the editor; news; comments; as well as results that were 
dissertations, thesis or abstracts published in conference 
proceedings or scientific journals.
The selected articles were subjected to content analy-
sis and those not assessing the causes related to the un-
derreporting of ADR by health professionals were elimi-
nated. The analysis of the articles were developed by two 
reviewers (FRV and SGP), with eventual disagreements 
resolved through discussion.
The variables of interest were defined through a con-
tent analysis involving the following criteria: year of pub-
lication, country in which the study was carried out, the 
study method (epidemiological approach), instruments 
and methodology used for assessing the cause of under-
reporting, level of health care, professional category in-
cluded in the study, adherence to the survey (response of 
professionals participating in the study), and the causes 
of underreporting according to the criteria described by 
Inman WHW(9). He was the first to present a list of seven 
attitudes related to the causes of underreporting, calling 
them the seven deadly sins:
1) complacency (believing that serious ADRs are well 
documented when the drug is released in the market); 
2) fear of getting involved in a lawsuit (legal process); 
3) guilt for having been responsible for the damage 
observed in the patient; 
4) ambition of group and publish case series or finan-
cial benefit; 
5) ignorance on how to describe the notification (be-
lieving that only serious and unexpected ADRs must be 
reported);
6) insecurity about reporting suspicions of ADR (belief 
that there should be notification only if there is certainty 
that the damage was caused by the use of specific medi-
cation); 
7) indifference, that is, lack of interest, time or other 
excuses related to postponing the notification of damage 
due to drug use.
RESULtS
In total, 149 potentially relevant articles were iden-
tified on the evaluated database. After reading the ab-
stracts, 117 articles were eliminated for not fitting the 
inclusion criteria. After content analysis, four articles were 
eliminated (Chart 1) and 29 were considered eligible for 
the study (Chart 2).
It was observed that most of the studies (N=16) were 
carried out in the European continent, especially at ter-
tiary level of health care (N=24) for physicians (N=22) and 
pharmacists (N=10). The experimental method most wide-
ly used for identifying the causes was the cross-sectional, 
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observational (N=24), with the questionnaire as the most 
used instrument (N=26). The response rate of the study 
subjects was greater than 50% in 21 studies, although 
three studies did not report these data. The main causes 
related to underreporting of adverse drug reaction were 
ignorance (N=24), insecurity (N=24) and indifference 
(N=23). No causes different than those established by 
Inman WHW have been identified(9). However, the data 
show the eighth sin of underreporting, which is the lack of 
training in pharmacovigilance.
Chart 2 - Studies that analyzed the causes related to underreporting of adverse drug events.
Study (year of 
publication)
Location  
Country Methods Results
Method Professional category
Level of 
health care
Sample 
size Instruments Adherence (%)
Causes of 
underreporting
Bateman et al.(14) England
Cross-sec-
tional,
Observational
Physicians Tertiary 1600
Pre-structured 
questionnaire 
by mail
74%
complacency (1)
fear of litigation (2)
ambition (4)
insecurity (6)
indifference (7)
Belton et al.(15) United King-dom
Cross-sec-
tional Physicians
Primary, 
secondary and 
Tertiary
500
Pre-structured 
questionnaire 
by mail
57%
complacency (1)
fear of litigation (2)
ambition (4)
insecurity (6)
indifference (7)
Belton and The 
Europen Pharmaco-
vigilance Research 
Group(16)
Member 
Countries of 
the European 
Union
Cross-sec-
tional Physicians Primary
Unin-
formed
Pre-structured 
questionnaire
Uninformed
Uninformed
complacency (1)
fear of litigation (2)
culpa (3)
ambition (4) 
ignorance (5)
insecurity (6)
indifference (7)
Cosentino et al.(17) Italy Cross-sec-tional Physicians Primary 350
Pre-structured 
questionnaire 
by mail
59,10%
ignorance (5)
insecurity (6)
Eland et al.(18) Holland Cross-sec-tional Physicians
Primary, 
secondary and 
tertiary
1984
Pre-structured 
questionnaire
Uninformed 
tertiary
68,40%
fear of litigation (2)
ignorance (5)
insecurity (6)
indifference (7)
Williams et al.(19) Ireland
Cross-section-
al, observa-
tional
Physicians Primary and tertiary 400
Pre-structured 
questionnaire 
by mail
39,50%
complacency (1)
fear of litigation (2)
ignorance (5)
insecurity (6)
indifference (7)
Bäckström et al.(20) Sweden Cross-sec-tional Physicians
Primary and 
tertiary 1274
Pre-structured 
questionnaire 
by mail
58,70%
complacency (1)
ignorance (5)
insecurity (6)
indifference (7)
Chart 1 - Studies excluded of the review after content analysis and rationale for not meeting the inclusion criteria
Author Rationale
Bäckström et al.(10) Estudio de intervención que evaluó el efecto de incentivo económico sobre la tasa de notificación espontánea de RAM.
Granas et al.(11)
Educational intervention study assessing the effect of an educational program on pharmacovigilance for pharmacists in 
Norway. They observed that lack of trust, time and knowledge about how to report an adverse reaction could prevent 
them from reporting.
Giraldo-Matamoros et al.(12)
Study of active search for ADRs reported by nurses in the pharmacovigilance system of Extremadura, a region of 
Spain. However, it did not analyze the factors related to non-adherence of this professional category in the pharma-
covigilance system.
González-Rubio et al.(13) Retrospective study that analyzed the notifications of the primary sector in Spain. The paper justifies that underreporting may have occurred due to ignorance and insecurity, but did not evaluate this data with health professionals.
Continued...
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Study (year of 
publication)
Location  
Country Methods Results
Method Professional category
Level of 
health care
Sample 
size Instruments Adherence (%)
Causes of 
underreporting
Figueiras et al.(21) Spain Case-control Physicians Primary 692
Pre-structured 
questionnaire 
by mail
Not reported
complacency (1)
ignorance (5)
indifference (7)
Green et al.(22) United King-dom
Cross-sec-
tional Pharmacists Tertiary 600
Pre-structured 
questionnaire 
by mail
53,70%
fear of litigation (2)
ambition (4) 
ignorance (5)
insecurity (6)
indifference (7)
Hasford et al.(23) Germany Cross-sec-tional Physicians
Primary, 
secondary and 
tertiary
1315
Pre-structured 
questionnaire 
by email
61,30%
complacency (1)
fear of litigation (2)
ignorance (5)
insecurity (6)
Li et al.(24) China Cross-sec-tional
Physicians, 
nurses and 
hospital 
administra-
tors
Tertiary 2000
Pre-structured 
questionnaire
Uninformed
85,00%
complacency (1)
guilt (3)
ambition (4) 
ignorance (5)
insecurity (6)
indifference (7)
Herdeiro et al.(25) Portugal Case-control Physicians Primary and tertiary 859
Pre-structured 
questionnaire 
by mail
46,20%
complacency (1)
ignorance (5)
insecurity (6)
indifference (7)
Vallano et al.(26) Spain Qualitative Physicians Tertiary 208
Focus group 
discussions 
and analysis of 
transcripts
100%
fear of litigation (2)
ignorance (5)
insecurity (6)
indifference (7)
Herdeiro et al.(27) Portugal Case-control Pharmacists Primary and tertiary 314
Pre-structured 
questionnaire 
by email
86,80%
complacency (1)
ignorance (5)
insecurity (6)
indifference (7)
Aziz et al.(28) Malaysia Cross-sec-tional Physicians
Primary and 
tertiary 415
Face-to-face 
pre-structured 
questionnaire
 (survey)
84,30%
ignorance (5)
insecurity (6)
Okezie et al.(29) Nigeria Cross-sec-tional Physicians Tertiary 220
Pre-structured 
questionnaire
Uninformed
91%
ignorance (5)
insecurity (6)
Ekman et al.(30) Sweden Cross-sec-tional Physicians Tertiary 1201
Pre-structured 
questionnaire 
by mail
54%
complacency (1)
ignorance (5)
insecurity (6)
indifference (7)
Nichols et al.(31) Canada Qualitative exploratory
Pharmacists 
and physi-
cians
Tertiary 36
Focus groups 
with phar-
macists and 
pre-structured 
surveys with 
physicians
100%
insecurity (6)
indifference (7)
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Study (year of 
publication)
Location  
Country Methods Results
Method Professional category
Level of 
health care
Sample 
size Instruments Adherence (%)
Causes of 
underreporting
Oshikoya et al.(32) Nigeria Cross-sec-tional Physicians Tertiary 120
Pre-structured 
form 82,50%
guilt (3)
ambition (4)
insecurity (6)
indifference (7)
Passier et al.(33) Holland Cross-sec-tional Physicians Primary 1490
Pre-structured 
questionnaire 
by mail
47%
fear of litigation (2)
ignorance (5)
indifference (7)
Vessal et al.(34) Iran Cross-sec-tional Pharmacists
Primary and 
tertiary 200
Pre-structured 
questionnaire 55%
complacency (1) 
fear of litigation (2)
ignorance (5)
insecurity (6)
indifference (7)
Gavaza et al.(35) United States Cross-sec-tional Pharmacists
Primary and 
tertiary 1500
Pre-structured 
questionnaire 
by mail
16,40%
fear of litigation (2)
ambition (4)
ignorance (5)
insecurity (6)
indifference (7)
Su et al.(36) China Cross-sec-tional Pharmacists Tertiary 288
Face-to-face 
structured 
questionnaire 
85,40%
complacency (1) 
ignorance (5)
insecurity (6)
indifference (7)
Bello & Umar(37) Nigeria Cross-sec-tional Physicians Tertiary 61
Pre-structured 
questionnaire
Survey
Uninformed
fear of litigation (2)
ignorance (5)
insecurity (6)
Desai et al.(38) India Cross-sec-tional Physicians Tertiary 426
Pre-structured 
questionnaire
Uninformed
61%
ambition (4) 
ignorance (5)
indifference (7)
Gavaza et al.(39) United States Cross-sec-tional Pharmacists
Primary and 
tertiary 1500
Pre-structured 
questionnaire 
by mail
26,40% indifference (7)
Oreagba et al.(40) Nigeria Cross-sec-tional Pharmacists Primary 400
Face-to-face 
pre-structured 
questionnaire
83% ignorance (5)
García et al. (41) Venezuela Cross-sec-tional
Pharmacists 
y physicians
Primary, 
secondary and 
tertiary
913 Face-to-face questionnaire 65,40%
ignorance (5)
insecurity (6)
indifference (7)
Pernas et al. (42) Portugal Cross-sec-tional
Physicians, 
nurses and 
pharmacists
Primary and 
tertiary 80
Pre-structured 
questionnaire 100,00%
complacency (1) 
fear of litigation (2)
guilt (3)
ambition (4)
ignorance (5)
insecurity (6)
indifference (7)
diSCUSSion
The pharmacovigilance underreporting is a global real-
ity evidenced by the identified studies, which were carried 
out in 17 different countries, and a multicenter study con-
ducted in the European Union. However, it was observed 
that most of the analyzed publications (N = 17) were car-
ried out in Europe (Germany, Spain, Holland, England, 
Ireland, Italy, Portugal, UK, Sweden). Such fact can be ex-
plained based on the tradition of these countries in the 
Program for International Drug Monitoring of the World 
Health Organization. In 1968, due to the presence of na-
tional ADR registration systems in Ireland, Holland, Swe-
den and the UK, these nations were invited to send ADR 
records for the WHO, in order to assess the safety of drugs 
available in the pharmaceutical market(43). 
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However, most of the countries in America, Africa and 
Asia joined the program afterwards (in the 1990s and 
2000), which leads to the assumption that pharmacovigi-
lance activities are more recent hence, only few studies 
were identified. For this reason, there is a need to better 
understand the factors associated with underreporting of 
problems related to drug use, and encourage voluntary 
reports by health professionals in these countries or Latin 
American countries.
The main epidemiological method and technique 
of data collection verified in this review was the cross-
sectional, observational study (N = 24), and use of self-
reported questionnaires (N = 15). These are relevant 
strategies to encourage surveys of this nature, especially 
in developing countries such as those from Latin Ameri-
ca, where only one study was identified. This is justified 
based on the benefits of cross-sectional studies, which 
are inexpensive, can be made in a short time frame, and 
are capable of creating research hypotheses to be inves-
tigated with more robust methodologies. Moreover, the 
identified papers that used this method obtained similar 
results in relation to the authors who carried out stud-
ies with larger level of evidence (case-control). A study(44) 
carried out the analysis of the characteristics of ADR re-
corded in the WHO-ADR database (Vigibase), correlat-
ing this information with the income profile of registrars 
countries. The authors found that the rates of notifica-
tion are lower in low-income countries, probably due to 
lack of knowledge and experience(11,13). This corroborates 
the necessity of encouraging studies in these countries 
with the use of cheaper methods.
Considering the application of self-reported ques-
tionnaires, the literature points the low rate of return of 
these instruments by study participants (mostly doctors) 
as the main limitation of this technique(45). The loss of 
more than 20% of the sample hampers conclusions with 
data for other populations, in addition to other factors 
such as convenience and sample size, method of study 
and biased results, considering that professionals who 
voluntarily answered the questionnaire possibly showed 
greater interest in the area of pharmacovigilance. How-
ever, the application of questionnaire by mail or email 
facilitates data collection, especially when respondents 
are geographically spread. Given this, a search(46) pro-
posed sending stamps for the responses and reminders 
of the return period to encourage subjects’ adherence 
to the survey.
Despite the limitations of collection methods and 
techniques, the main causes of ADR underreporting 
found in the included studies were ignorance and inse-
curity. This has a strong correlation with professionals’ 
low knowledge about the activities of analysis of drug 
safety. Such fact was the most common cause for non-
adherence of professionals to pharmacovigilance ser-
vice, confirming a study hypothesis that evaluated the 
condition of notifications.
Thus, the notifications of professionals may be encour-
aged by promoting educational interventions aimed at 
clarifying the importance of the practice. As well as the 
concepts and processes involved in these activities, name-
ly: which ones should be recorded (any suspected adverse 
drug events), who can register, and the return to society 
(patient safety), health facilities (reduction of unnecessary 
costs) and the pharmaceutical market (control and regula-
tion). Studies show that continuing education for health 
professionals are effective in changing attitudes and behav-
ior in relation to registration of adverse drug events, nota-
bly ADR(47-48). Hence, economic costs are optimized due to 
the incentive on rates of voluntary registration of ADR(20).
Another cause of underreporting frequently reported by 
physicians and pharmacists included in the study is indiffer-
ence, mainly associated with the lack of interest in registra-
tion, lack of time for too many activities in the clinical routine, 
among others. As an attempt to solve this problem, the ADR 
reporting by the own users of drugs is a positive perspec-
tive(49). In addition, making the access to registration forms 
easier and simplifying documents(1), would contribute to im-
prove the notification rates of problems related to medica-
tion, as well as facilitating communication between registrars 
and pharmacovigilance centers (such as the Rede Sentinela, 
a project developed in Brazil that encourages pharmacovigi-
lance activities in hospitals, aimed at enabling the analysis of 
safety, quality and effectiveness of medicines), and encour-
aging feedback from the results of reports (26,31,35). 
Studies evaluating the attitudes of nursing staff(24,42) 
found that the lack of knowledge in completing the no-
tification form, and the lack of time to report ADRs are 
the main causes of underreporting in this class. Therefore, 
strategies must be developed to improve the adhesion 
of these professionals to the pharmacovigilance service. 
As these professionals are responsible for administering 
medications and assisting by the bedside, they can con-
tribute to identify suspected problems of safety and ef-
fectiveness of drugs(50), especially serious ADR(51) that are 
unexpected. Thus, the training and qualifications of nurs-
ing staff may allow the development of competencies 
and skills for behavior change in relation to the sponta-
neous reporting. A study(52) verified that the completion 
of training by nurses is essential to optimize their roles in 
pharmacovigilance actions. In addition, health institutions 
should strengthen nonpunitive management for the ad-
ministration of risks associated with drug therapy.
Health institutions are changing the way they manage 
risk (from personal to systemic)(53), and encouraging the 
notification of adverse events to drugs by health profes-
sionals, in order to improve processes and not to identify 
the author, causing fear of punishment and retaliation in 
these professionals, which is a major barrier to promote 
the reporting of drug related problems. Thus, ensuring 
the confidentiality and secrecy of people reporting the 
data avoids their exposure and encourages their participa-
tion in the analysis of drug safety(54).
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The great interest in compiling and publishing case 
series was one of the causes of underreporting less fre-
quently mentioned by professionals, perhaps because this 
is more related to the interests of researchers associated 
with universities. However, all records resulting from sci-
entific investigations should not be dissociated from the 
regulatory acts. Therefore, they should be given to regu-
latory health agencies for feeding the database, contrib-
uting to signal generation in pharmacovigilance and im-
proving communication of the risks associated with drug 
use. Considering financial benefits, such as encouraging 
registration of ADR through salary increases or bonuses 
for example, is a questionable strategy, since no impact of 
this incentive was found on ADR reporting in a study car-
ried out in a Spanish hospital(55).
Finally, it is necessary to know the causes that lead to 
non-compliance with pharmacovigilance service in order 
to strongly encourage the reporting of ADR by health pro-
fessionals, because many strategies can be used and de-
veloped for reducing this problem to a minimum. Thus, 
the best action plan may be designed, considering the 
needs and aspirations of the people who report the cases, 
the available resources for strategies implementation and 
the frequency with which they should applied. Therefore, 
studies of this nature should be carried out primarily in 
the American continent to indirectly contribute with the 
harmonization of patient safety plans.
Finally, the underreporting causes often informed by 
health professionals are related mainly to the low knowledge 
of concepts and processes related to pharmacovigilance and 
to indifference regarding this service. Continuing education, 
easy access to the registration form and its simplification are 
strategies that can be developed to increase the registration 
rates of ADR by health professionals. Furthermore, low cost 
epidemiological methods (cross-sectional, observational 
type) are able to detect similar underreporting causes when 
compared with methods of higher levels of evidence. This 
allows that developing countries like those of Latin America 
carry out studies aimed at investigating the reasons associ-
ated with low adherence of health professionals to pharma-
covigilance service and demystify prejudices about the con-
sequences of underreporting.
The limitation of the study was that the data obtained 
may be underestimated because of the selection strategy. 
Five databases were consulted and the only articles con-
sidered eligible were those written in Portuguese, English 
and Spanish, plus eight articles not available to consulta-
tion, which were then eliminated from the review. In ad-
dition to that, every author had an own interpretation of 
the seven sins of Inman, which can have been different 
from those considered in this review.
ConCLUSion
This study allowed adding the eighth deadly sin in un-
derreporting: the lack of training in pharmacovigilance 
for health professionals. However, qualitative studies are 
needed to better understand this phenomenon.
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